Figure 4From: Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trialDyspnoea on the Transition Dyspnoea Index at Week 26 (a) TDI focal score at Week 26 (b) Patients achieving ≥ 1 point improvement in TDI at Week 26. TDI = Transition Dyspnoea Index (≥ 1 point is the minimum clinically important difference [MCID]).Back to article page